| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 37 | 60.8x | 17.8x | Bottom tier | |
Growth | 50 | 4.1% | 7.1% | Around median | |
Quality | 75 | 6.5% | 4.5% | Top tier | |
Safety | 37 | 4.1x | 2.6x | Bottom tier | |
Capital Return | 77 | — | 2.12% | Top tier | |
Momentum | 89 | 87.3% | 2.9% | Top tier | |
Sentiment | 46 | 8 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Teva Pharmaceutical Industries Limited operates in innovative medicines, generics, and biosimilars, and is gradually transitioning from a generics-led model to a biopharmaceutical company with a higher-value mix. In Q2 fiscal 2026, its innovative portfolio grew 43% year over year, driven by AUSTEDO, AJOVY, and UZEDY, while generics declined 15%, primarily due to the reduced contribution from generic REVLIMID; excluding this product, management said the generics business remained stable, while Teva had fifteen biosimilars on the market and fourteen in development.
Revenue in Q2 fiscal 2026 was approximately $4.1 billion, down 1% in U.S. dollars and 3% in local currencies year over year, and the company recorded a GAAP net loss of $576 million and a loss per share of $0.49. Gross profit according to EDGAR data was approximately $2.2 billion, equivalent to a calculated gross margin of about 53.7%, while non-GAAP gross margin was 55.4%, up 80 basis points due to the increased weight of innovative products.
Within the innovative mix in Q2 fiscal 2026, AUSTEDO generated U.S. revenue of $676 million and global growth of 40%, AJOVY global revenue reached $244 million with growth of 56%, and UZEDY achieved record sales of $77 million with growth of 43%. Conversely, the Amylyx acquisition, which closed in June 2026, weighed on net income through the recognition of $724 million in in-process research and development expenses, while quarterly free cash flow rose 31% to $622 million.
The analyst consensus is “Buy,” with an average price target of $42.67 and a narrow range of $42 to $44; the average is above the upper end of the 52-week range of $38.37, while the annual range extends from $17.89 to $38.37. Conversely, this optimism should be weighed against the Q2 fiscal 2026 loss of $576 million, the decline in generics, and the dependence of part of the rerating on continued growth in AUSTEDO, AJOVY, and UZEDY and the success of upcoming regulatory catalysts.
Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.
The primary driver came from the innovative portfolio, whose revenue grew 43% year over year. AUSTEDO achieved global growth of 40%, UZEDY rose 43% to $77 million, while AJOVY grew 56% to $244 million. This momentum offset a large portion of the 15% decline in generics, but total revenue remained down 1% at approximately $4.1 billion.
The company recorded a GAAP net loss of $576 million and a loss per share of $0.49. The largest factor was the recognition of $724 million in in-process research and development expenses associated with the Amylyx acquisition, which closed in June 2026. On a non-GAAP basis, earnings per share were $0.02, but they would have been $0.63 excluding the Amylyx impact of $0.61 per share.
AUSTEDO revenue in the United States reached $676 million in Q2 fiscal 2026, and global revenue grew 40% year over year. Total prescriptions increased 14% and milligrams increased 21%, while AUSTEDO XR accounted for more than 60% of new patients for the product. Teva raised its fiscal 2026 revenue guidance range to $2.45–$2.60 billion, but expects its revenue to decline year over year in Q4 fiscal 2026 due to inventory, purchasing patterns, and pricing ahead of January 2027.
Automated analysis for informational purposes only — not investment advice.
UZEDY generated record revenue of $77 million in Q2 fiscal 2026, up 43%, with total prescriptions growing 63% and its share of the long-acting risperidone market rising from 5% to nearly 10%. Teva therefore raised its fiscal 2026 UZEDY revenue guidance to $270–$290 million. AJOVY global revenue reached $244 million with growth of 56%, prompting the company to raise its annual guidance to $850–$870 million.
On August 19, 2026, the U.S. Food and Drug Administration accepted the ecopipam application for treating Tourette syndrome in children and granted it priority review. The regulatory decision is scheduled for late Q1 fiscal 2027, and the company says the market includes approximately 100,000 pediatric patients, only 50,000 of whom are treated. Development data showed a 50% reduction in the relapse rate in a Phase 3 study, while 66% of patients remained on treatment during long-term follow-up with the reduction in tics sustained.
Net debt reached $12.9 billion at the end of Q2 fiscal 2026, and the net debt-to-EBITDA ratio reached 2.8 times. The ratio would have been 2.3 times excluding the Amylyx impact, compared with the company’s target of 2 times by fiscal 2027. Fitch upgraded Teva to investment grade in May 2026, and news on August 11, 2026, reported that Moody’s raised the rating to Baa3 with a stable outlook, alongside a 31% increase in quarterly free cash flow to $622 million.
